-
Amiculum
-
Who we are
-
What we do
-
Insights
-
Vaccine reimbursement in low- and middle-income countries: bridging the gap between innovation and access
-
Amiculum meets Ashifa Trivedi: what does meaningful partnership with children and young people in healthcare really look like?
-
Personalization, automation and actionable intelligence: How to achieve purposeful innovation in healthcare communications
-
The impact of AI on publications
-
Simultaneous publications: profiling this prevalent practice and planning for success
-
A simplified three-step process for achieving the fundamentals of omnichannel engagement in pharma: how to deliver impactful, connected experiences
-
Who shapes medical decisions now? KOLs, DOLs, VOLs and the future of Medical Affairs engagement
-
PharmaQuest returns: EPA perspectives, through a rare disease lens
-
Navigating the new ‘most-favoured nation’ (MFN) reality: are pharma companies ready?
-
MedAffairs Transformation Congress: advancing the strategic role of Medical Affairs
-
Amiculum meets Paul Tunnah: Pharma’s adoption of AI in healthcare communications
-
Can we trust LLMs to provide appropriate medical advice?
-
What does impactful medical education look like for rare diseases
-
Amiculum insights podcast: highlights from ISMPP Europe 2026
-
From ‘why’ to ‘how’: patient partnership across age groups in research and publications
-
Turn payer insights into impact with omnichannel engagement in market access
-
How can pharma build genuine partnerships with patient communities?
-
What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends
-
Winning in Pharma: the power of early strategic planning with patients
-
AI persona generation for healthcare: quick wins & real-world impact
-
Adapting market access strategies: Practical takeaways from ISPOR Europe
-
What defines the ideal therapy today? Insights from PharmaQuest at ISPOR Europe
-
Can AI drive efficiency in systematic literature reviews?
-
Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?
-
AI in Pharma: Insights from GlobalLink NEXT London 2025
-
Is AI the answer? Translating complex medical information into public understanding
-
Unlocking the future of Learning
-
Real-world implementation of AI in medical affairs: Vision, value and collaboration
-
Why healthcare communications needs creativity, now more than ever
-
The (clinical) trials and tribulations of gene therapy - why meaningful patient engagement strategies matter
-
Data visualization: translating complex data into emotive storytelling
-
What do people look for in gene therapy materials? Results from our survey of patients and relatives
-
What’s next for scientific congress booths: five trends for 2025
-
Can AI reliably replace human reviewers in literature reviews?
-
Stacking the odds in your favour with landscape analysis
-
AI in market access: silver bullet or spanner in the works?
-
Answering some of Pharma’s big questions to drive brand strategies
-
Unlocking market access success for cell and gene therapies: the vital role of early strategic planning
-
Artificial intelligence versus real insight – does pharmaceutical industry consulting face a dilemma or a progression?
-
Generative AI, storytelling and patient inclusion: key publications trends in 2024
-
Joint Clinical Assessments: bureaucratic nightmare, AI opportunity, or both?
-
Eyes on the horizon: six (and a half) predictions for the future of healthcare communications
-
Do omnichannel approaches have a role in market access and payer discussions?
-
Early strategic planning: how to get ahead of the curve
-
Enhancing the patient–HCP relationship in rare diseases
-
Bringing omnichannel to medical affairs: what do you need to know?
-
News
-
Join us
-
Contact
-
Cookie Policy
-
Privacy Policy
-
Supplier Code of Conduct
-
Accessibility Statement
-
Terms and Conditions
-
Company Details